Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) issued its earnings results on Monday. The company reported ($0.74) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.47 million during the quarter.
Lixte Biotechnology Trading Down 7.7%
Shares of NMAD stock traded down $0.23 during trading hours on Wednesday, hitting $2.77. 11,381 shares of the company’s stock were exchanged, compared to its average volume of 201,659. The company has a market capitalization of $44.60 million, a PE ratio of -2.77 and a beta of 1.37. Lixte Biotechnology has a 12-month low of $2.15 and a 12-month high of $8.38. The business’s 50 day simple moving average is $3.71 and its 200-day simple moving average is $4.65.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on NMAD. Weiss Ratings raised shares of Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a report on Friday, September 25th. Wall Street Zen cut Lixte Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.
Get Our Latest Report on Lixte Biotechnology
Institutional Investors Weigh In On Lixte Biotechnology
A number of institutional investors have recently made changes to their positions in NMAD. Legacy Wealth Managment LLC ID bought a new stake in Lixte Biotechnology in the second quarter worth $4,457,000. BlackRock Inc. purchased a new stake in Lixte Biotechnology during the second quarter valued at about $564,000. FNY Investment Advisers LLC purchased a new stake in Lixte Biotechnology during the second quarter valued at about $330,000. Finally, Equitable Holdings Inc. bought a new position in shares of Lixte Biotechnology during the second quarter valued at about $74,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.
About Lixte Biotechnology
Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.
Read More
- Five stocks we like better than Lixte Biotechnology
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
